Drug pricing for your ears: The 46brooklyn Podcast is officially launched!

46brooklyn Research was launched in August 2018 with the goal of improving the accessibility and usability of U.S. drug pricing data. That means that we've spent nearly four years building and analyzing drug pricing dashboards and providing our insights on the field of play within the prescription drug supply chain.

We've learned a lot in that time, and we hope you have too.

To that end, while we have spent ample time over the years discussing our learnings in a number of mediums, we have received a number of requests to create a platform to bring that content to the earbuds.

Today, after months of prep work, recognizing that everyone learns differently, we are excited to announce that we are fulfilling those requests, and we are formally launching The 46brooklyn Podcast.

On the podcast, we will dive into a number of the issues that our team is exploring, highlight the latest trends in drug pricing, conduct interviews with some of the brightest minds working in and around the drug channel, and much, much more.

In conjunction with the announcement of our podcast launch, we are leaning into our Star Wars bonafides by releasing a prequel series entitled, "Drug Pricing 101."

The purpose of this series is to provide a baseline understanding of the drug channel participants, some of the incentives that guide their behavior, and how they impact the many different ways that we quantify the price of a drug – which if you've followed along over the years, you should already know there is no such thing as a singular price.

This series should serve as an admittedly nerdy traversing through the basic fundamentals of the drug channel and pricing benchmarks that will help better equip listeners with necessary nuance and context not just for follow-up episodes of the podcast, but for broader drug pricing understanding as a whole.

Our hope with this podcast – and all our work at 46brooklyn – is that better awareness and education will help improve the accountability of our prescription drug supply chain and, in time, lead to the much-needed simplification of how drugs are priced.

Special thanks to Benjamin Rivet at JRNYMN Productions for the music, sounds, and edits to the podcast. This wouldn't have been possible without his tremendous expertise.

And additional thanks to the fantastic folks at McGohan Brabender for use of their high-tech recording studio. Scott McGohan is a founding board member at 46brooklyn and continues to be a true leader in seeking truth within prescription drug pricing.